Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- CPKCRecord $4.95 million raised for heart health in Alberta as Miyu Yamashita wins CPKC Women's OpenThe 2026 CPKC Women's Open raised a record $4.95 million to support heart healthcare in Alberta, while on the golf course, Miyu Yamashita concluded a historic performance on Sunday to capture the 2026 CPKC Women's Open and her fourth LPGA Tour...
- Antengene Corporation LimitedAntengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&DAntengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...
- AnBogen TherapeuticsAnbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication ExpansionAnbogen Therapeutics Inc. (TPEx: 7784) ("Anbogen" or the "Company"), a clinical-stage precision oncology company, today announced that it has entered into a Collaborative Research Agreement (CRA) with the Laboratory of Veterinary Surgery, Graduate...
- InterSystems Asia READY 2026 to Showcase AI-Ready HealthcareBANGKOK, August 24, 2026--InterSystems, a creative data technology provider managing over one billion healthcare records globally, will bring healthcare leaders from across Asia to Bangkok for InterSystems Asia READY 2026, where the focus will be on how trusted data, interoperability, and practical artificial intelligence (AI) can accelerate smarter healthcare delivery and strengthen Thailand's position as a regional medical hub.
- Shape Memory Medical Inc.Shape Memory Medical Secures $10 Million Financing Led by August Global Partners to Advance Aortic Clinical ProgramsSAN JOSE, Calif., August 24, 2026--Shape Memory Medical Inc., developer of proprietary shape memory polymer technology for endovascular embolization, today announced the closing of a $10 million convertible note financing led by new investor August Global Partners (AGP), joined by fellow new investor Taiwania Capital.
- Novotech Strengthens Presence in Japan with Opening of Tokyo OfficeSINGAPORE, August 23, 2026--Novotech, a leading global biotech full service CRO, has strengthened its established presence in Japan with the opening of a new office in Tokyo.
- Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody ConjugateOrum receives FDA clearance for ORM-1153, advancing its novel CD123-GSPT1 degrader-antibody conjugate toward Phase 1 in hematologic malignancies.
- American Association of Nurse AnesthesiologyAANA Launches Anesthesia Answers, a Patient Education Resource Built by CRNAs/Nurse AnesthesiologistsThe American Association of Nurse Anesthesiology (AANA) today announced the launch of Anesthesia Answers, a new patient education resource created by Certified Registered Nurse Anesthetists (CRNAs)/nurse anesthesiologists to help patients and...
- SuperiorMed Holdings Limited Announces Entering into an Agreement and Plan of Merger with Starry Sea Acquisition CorpSuperiorMed Holdings Limited, a Cayman Islands company (“SuperiorMed” or the “Company”), a company that shall become the parent company of SuperiorMed Healthcare Management FZ-LLC, a company in the business of management and consulting service for certain medical institutions under the laws of the United Arab Emirates (“UAE”), announced today that it has entered into an Agreement and Plan of Merger (the “Merger Agreement”) on August 22, 2026 for a business combination with Starry Sea Acquisition Corp (Nasdaq: SSEA, SSEAU, SSEAR), a special purpose acquisition company incorporated in the Cayman Islands (“SSEA”).
- Zura Bio LimitedZura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)HENDERSON, Nev., August 21, 2026--Zura Bio Limited (Nasdaq: ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on August 20, 2026, the Company granted inducement awards consisting of options to purchase up to 587,000 Class A Ordinary Shares (the "Options") to thirteen newly hired employees. These a
- Hagens Berman Sobol Shapiro LLPRegeneron Pharmaceuticals, Inc. Notice of September 14, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application DeadlineHagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma.The news that the trial failed drove the price of Regeneron shares sharply lower and, along with the severe market reaction ($11 billion market cap wipeout),...
- Memodyne Details 2026 Cognitive Formula Ingredient Profile Featuring L-Arginine, L-Citrulline, and NiacinMemodyne's supplement label, USA manufacturing, and brain health category context are outlined for daily wellness comparison shoppers.